Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch

Strengthens balance sheet to support commercial readiness and planned U.S. launch of AD109 oral pill for the treatment of Obstructive Sleep Apnea (OSA) On track to submit New Drug Application (NDA) for AD109 later this quarter CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ — Apnimed, Inc., a pharmaceutical company developing novel oral therapies for obstructive sleep…

Your browser is not supported

Your browser is not supported | dispatch.com dispatch.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on…

No Cookies | The Australian

Please note that by blocking any or all cookies you may not have access to certain features, content or personalization. For more information see our Cookie Policy. To enable cookies, follow the instructions for your browser below. Facebook App: Open links in External Browser There is a specific issue with the Facebook in-app browser intermittently…